Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of “Hold” by Analysts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has been assigned a consensus recommendation of “Hold” from the twenty-nine analysts that are presently covering the company, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a sell recommendation, fourteen have given a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $34.4583.

A number of research analysts have recently issued reports on SRPT shares. Jefferies Financial Group cut their target price on shares of Sarepta Therapeutics from $40.00 to $35.00 and set a “buy” rating for the company in a research note on Thursday, July 24th. Barclays upgraded shares of Sarepta Therapeutics from an “underweight” rating to an “equal weight” rating and set a $22.00 target price for the company in a research note on Tuesday, July 29th. HC Wainwright restated a “sell” rating on shares of Sarepta Therapeutics in a research report on Monday, August 25th. Morgan Stanley boosted their price objective on shares of Sarepta Therapeutics from $15.00 to $20.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 29th. Finally, Wall Street Zen upgraded shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $23.50 on Tuesday. Sarepta Therapeutics has a 1 year low of $10.41 and a 1 year high of $138.81. The firm has a 50 day moving average of $19.95 and a 200-day moving average of $27.75. The company has a current ratio of 2.89, a quick ratio of 1.81 and a debt-to-equity ratio of 0.84. The stock has a market capitalization of $2.30 billion, a P/E ratio of -27.01 and a beta of 0.51.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $1.13. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The company had revenue of $611.09 million during the quarter, compared to analysts’ expectations of $530.66 million. During the same quarter in the previous year, the company posted $0.07 earnings per share. Sarepta Therapeutics’s quarterly revenue was up 68.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Louisiana State Employees Retirement System raised its position in Sarepta Therapeutics by 1.1% in the 1st quarter. Louisiana State Employees Retirement System now owns 26,800 shares of the biotechnology company’s stock worth $1,710,000 after purchasing an additional 300 shares during the last quarter. State of Michigan Retirement System raised its position in shares of Sarepta Therapeutics by 1.3% during the 1st quarter. State of Michigan Retirement System now owns 22,900 shares of the biotechnology company’s stock valued at $1,461,000 after acquiring an additional 300 shares during the last quarter. Ancora Advisors LLC raised its position in shares of Sarepta Therapeutics by 150.0% during the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 300 shares during the last quarter. Cambridge Investment Research Advisors Inc. raised its position in shares of Sarepta Therapeutics by 5.9% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 6,387 shares of the biotechnology company’s stock valued at $408,000 after acquiring an additional 358 shares during the last quarter. Finally, GF Fund Management CO. LTD. raised its position in shares of Sarepta Therapeutics by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 2,446 shares of the biotechnology company’s stock valued at $156,000 after acquiring an additional 440 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.